课题基金 / 基金详情

Biomarker Discovery for Early Detection of Pancreatic Ductal Adenocarcinoma

Biomarker Discovery for Early Detection of Pancreatic Ductal Adenocarcinoma
早期检测胰腺导管腺癌的生物标志物发现
批准号:
7962113
负责人:
CHRISTOPHER KLUG
金额:
$60.53万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-03-01 至 2015-02-28

项目摘要

项目成果

CHRISTOPHER KLUG的其他基金

相似基金

相关文献

中文摘要
翻译
项目概述(见说明):
英文摘要
PROJECT SUMMARY (See instructions): Infiltrating pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal human malignancies, with an overall five-year survival rate of less than five percent. The high mortality rate associated w/ith PDAC is primarily due to the late stage at which disease is diagnosed and the resistance of pancreatic cancer to traditional chemotherapy and radiotherapy treatment approaches. These observations highlight the critical need for early detection of pancreatic neoplasia at a stage where surgical resection can be curative. The major goal of this proposal will be to use state-of-the-art mass spectrometry and genetically engineered mouse models representing preinvasive or early, organ-confined stages of pancreatic neoplasia to identify a comprehensive set of biomarkers that can be used in combination to prospectively diagnose early neoplasic disease in humans. In Aim 1, we will identify serum biomarkers in genetically inbred mice that express an activated allele of Kras (KrasG12D) in the pancreatic ductal epithelium and in mice with KrasG12D expressed on a p16lnk4a- or p53-deficient background. Constitutive activation of KRAS is observed in over 90% of PDAC cases and it likely represents one of the earliest genetic lesions in pancreatic cancer. Aim 2 will utilize newly-derived pancreatic ductal cell lines from the same animal models described in Aim 1 to characterize the complete spectrum of changes that occur in the cell-surface proteome and in the secretome as neoplasia progresses from preinvasive lesions to fully metastatic disease. In Aim 3, we will utilize histology-guided MALDI-TOF MS tissue profiling to identify biomarkers associated with early-stage pancreatic neoplasia using pancreatic tissue from the animal models. From these results, we expect to compile a comprehensive set of biomarkers for detection of early-stage pancreatic cancer. Finally, in Aim 4, we will test the specificity and sensitivity of the early-stage biomarkers identified in the murine system for their ability to diagnose pancreatic neoplasia using human serum samples collected from healthy donors and cases representing chronic pancreatitis and PDAC. The goal of these studies will be the development of an antibody-based diagnostic assay that can be used to screen high-risk patients for pancreatic cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining the role of Wnt11 and Wnt5a in regulating hematopoietic and skeletal stem cell self-renewal potential during homeostasis and stress
Defining pathways promoting HSC self-renewal by mesenchymal stem/stromal cells
Regulation of hematopoietic stem cell self-renewal by NUP98-HOXA9
Regulation of hematopoietic stem cell self-renewal by NUP98-HOXA9
海外基金